Similarly, EpCAM, a widespread marker on epithelial carcinomas, and MUC1, a glycoprotein aberrantly glycosylated in gastric tumors, serve as attractive targets for next-generation CAR-T constructs [58,59]. This evidence concerns the gene EPCAM and gastric neoplasm.